Dosing and Administration

Dosing and Administration

High-Dose Bolus Regimen

High-Dose Bolus Regimen

Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance (CrCl) ≤60 mL/min, give 25 mcg/kg bolus within 5 minutes followed by an infusion of 0.075 mcg/kg/min for up to 18 hours.

Administration

The following videos provide detailed instructions on how to use Aggrastat® High-Dose Bolus.

View now to see best practices for storing, dosing, and administering Aggrastat®.

Bolus Vial (250 mcg/mL)

Please see Important Safety information below and at the end of the video.

100 mL Vial / 250 mL Bag (50 mcg/mL Units)

Please see Important Safety information below and at the end of the video.

Drug Compatibilities

Aggrastat® can be administered in the same intravenous line as heparin, atropine sulfate, dobutamine, dopamine, epinephrine hydrochloride (HCl), famotidine injection, furosemide, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, and propranolol HCl. Do not administer Aggrastat® through the same IV line as diazepam. Do not add other drugs or remove solution directly from the bag with a syringe.

Instructions for Bags

To open the premixed bag, first tear off its foil overpouch. The plastic may be somewhat opaque because of moisture absorption during sterilization; the opacity will diminish gradually. Check for leaks by squeezing the inner bag firmly; if any leaks are found or sterility is suspect then the solution should be discarded. Do not use unless the solution is clear and the seal is intact.

Instructions for 100 mL Vial

Ensure seal is intact. Remove vial cap. Place vial on a flat surface, insert a vented IV set and open the vent. Hang bottle by plastic hanger and adjust flow for appropriate dosing.

Dosing Formulas

Dosing Formulas

Dosing Calculator

Administration Options:
 Patient Weight (kg):
Creatinine Clearance:
  

Results
1. Bolus
(Using 250 mcg/mL Bolus Vial)
Volume (mL): 		2. Infusion
(Using 50 mcg/mL Units)
Rate (mL/hr):

Disclaimer

By using this resource, you agree to the following: This Dosing Calculator is being provided "AS IS" and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Medicure makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Medicure, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.

Download Resources

Download or request Aggrastat® resources for your hospital.

Contact Medical Affairs

Contact Medical Affairs for clinical questions regarding Aggrastat®.
Important Safety Information  |  Prescribing Information
Important Safety Information  |  Prescribing Information

IMPORTANT SAFETY INFORMATION

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.

Privacy Policy  |  Terms of Use  |  Medicure  |  Contact

Copyright © 2020 Medicure Pharma. All rights reserved.

Unite Interactive